New molecular entity
Development and Regulatory status
Phase III Clinical Trials
First in class inhibitor of DNA gyrase (topoisomerase type II)
Gonorrhoea diagnoses in the UK increased by 80% between 2013 and 2018; up to mid-2019 resistance to first-line antibacterials, including ceftrixone and azithromycin, continued to increase from previous levels. Azithromycin resistance has reached the point where it is no longer recommended as first-line therapy .